Literature DB >> 33871567

SARS-CoV-2 spike therapeutic antibodies in the age of variants.

Alina Baum1, Christos A Kyratsous1.   

Abstract

Christos Kyratsous, Vice President of Research, Infectious Diseases, and Viral Vector Technologies at Regeneron Pharmaceuticals, and Alina Baum, Associate Director, Infectious Diseases Associate at Regeneron Pharmaceuticals, discuss the development of antibody therapeutics targeting the spike protein of SARS-CoV-2.
© 2021 Baum and Kyratsous.

Entities:  

Year:  2021        PMID： 33871567     DOI： 10.1084/jem.20210198

Source DB:  PubMed          Journal:  J Exp Med        ISSN： 0022-1007            Impact factor:   14.307


  4 in total

Review 1.  Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.

Authors:  William R Strohl; Zhiqiang Ku; Zhiqiang An; Stephen F Carroll; Bruce A Keyt; Lila M Strohl
Journal:  BioDrugs       Date:  2022-04-27       Impact factor: 7.744

Review 2.  Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications.

Authors:  Aakriti Dubey; Shweta Choudhary; Pravindra Kumar; Shailly Tomar
Journal:  Curr Microbiol       Date:  2021-12-14       Impact factor: 2.188

3.  Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days.

Authors:  Erin K McCreary; J Ryan Bariola; Tami Minnier; Richard J Wadas; Judith A Shovel; Debbie Albin; Oscar C Marroquin; Mark Schmidhofer; Mary Kay Wisniewski; David A Nace; Colleen Sullivan; Meredith Axe; Russell Meyers; Tina Khadem; William Garrard; Kevin Collins; Alan Wells; Robert D Bart; Kelsey Linstrum; Stephanie K Montgomery; Ghady Haidar; Graham M Snyder; Bryan J McVerry; Christopher W Seymour; Donald M Yealy; David T Huang; Derek C Angus
Journal:  Contemp Clin Trials       Date:  2021-12-09       Impact factor: 2.226

4.  Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth.

Authors:  Zhiqiang Ku; Xuping Xie; Jianqing Lin; Peng Gao; Abbas El Sahili; Hang Su; Yang Liu; Xiaohua Ye; Xin Li; Xuejun Fan; Boon Chong Goh; Wei Xiong; Hannah Boyd; Antonio E Muruato; Hui Deng; Hongjie Xia; Zou Jing; Birte K Kalveram; Vineet D Menachery; Ningyan Zhang; Julien Lescar; Pei-Yong Shi; Zhiqiang An
Journal:  bioRxiv       Date:  2022-02-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.